Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vigil Neuroscience Inc (VIGL – Research Report), reducing the price ...
The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.
The FDA granted regenerative medicine advanced therapy (RMAT) status to experimental cell therapy Lomecel-B for mild ...
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic ...
It’s approved by the Food and Drug Administration (FDA ... the medication and those who were less likely to develop cognitive ...
Alzheimer’s has no cure and can’t be reversed, but the FDA-approved drug can slow cognitive decline. Eli Lilly reported that ...
The company looks to tackle the Alzheimer's market by supplying global diagnostics firms with the antibodies needed for their tests in the space.
The US Food and Drug Administration approved Donanemab, also called Kisunla. Tuesday's decision put the monoclonal antibody ...
FDA designation enables expedited clinical development and regulatory review timelines for Lomecel-B™ –– Second designation received for ...
It's not a cure-- but it is a step in the right direction.This month-- a new medication for alzheimer's, called 'kinsul'a, ...
This article summarizes current health news encompassing topics such as funding for Alzheimer's drug development, the launch ...
Yesterday was a big day for European biotechs. As if CatalYm’s $150 million series D round wasn’t enough for one day, the ...